Merck & Co and Japan’s Eisai have reached a deal to develop and sell two of their cancer drugs, which are already approved as separately and in combination therapies, in a deal that could ...

The global Tissue Diagnostic Market is valued at USD 8.81 billion in 2024 and is projected to reach a value of USD 19.01 ...

The real-world evidence solutions market is largely driven by the increasing prevalence of chronic diseases and their impact on real-world healthcare ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

The global Isooctyl Alcohol market is set to achieve a significant milestone by reaching a valuation of USD 723.6 million by ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Valued at a market cap of $204.3 billion, Merck & Co., Inc. (MRK) is a global healthcare company with a diverse portfolio ...

Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S.

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.